BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36173459)

  • 1. Molecular imaging of sarcomas with FDG PET.
    Mendoza H; Nosov A; Pandit-Taskar N
    Skeletal Radiol; 2023 Mar; 52(3):461-475. PubMed ID: 36173459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
    Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC
    Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of
    Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
    Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Metser U; Kulanthaivelu R; Salawu A; Razak A; Mak V; Li X; Langer DL; MacCrostie P; Singnurkar A
    J Nucl Med; 2023 Sep; 64(9):1371-1377. PubMed ID: 37414444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
    Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
    PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
    Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
    BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors.
    Peterson JJ
    Semin Musculoskelet Radiol; 2007 Sep; 11(3):246-60. PubMed ID: 18260035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages of
    Németh Z; Boér K; Borbély K
    Pathol Oncol Res; 2019 Jan; 25(1):131-136. PubMed ID: 28994004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin.
    Katal S; Gholamrezanezhad A; Kessler M; Olyaei M; Jadvar H
    PET Clin; 2018 Oct; 13(4):609-621. PubMed ID: 30219191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
    Völker T; Denecke T; Steffen I; Misch D; Schönberger S; Plotkin M; Ruf J; Furth C; Stöver B; Hautzel H; Henze G; Amthauer H
    J Clin Oncol; 2007 Dec; 25(34):5435-41. PubMed ID: 18048826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET with
    Harrison DJ; Parisi MT; Khalatbari H; Shulkin BL
    PET Clin; 2020 Jul; 15(3):333-347. PubMed ID: 32498989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of positron emission tomography in the management of patients with sarcoma.
    Benz MR; Tchekmedyian N; Eilber FC; Federman N; Czernin J; Tap WD
    Curr Opin Oncol; 2009 Jul; 21(4):345-51. PubMed ID: 19412096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-Analysis of the Diagnostic Accuracy of Primary Bone and Soft Tissue Sarcomas by 18F-FDG-PET.
    Younis MH; Abu-Hijleh HA; Aldahamsheh OO; Abualruz A; Thalib L
    Med Princ Pract; 2020; 29(5):465-472. PubMed ID: 31887730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of
    Kassem TW; Abdelaziz O; Emad-Eldin S
    Diagn Interv Imaging; 2017 Oct; 98(10):693-698. PubMed ID: 28734778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional image in soft tissue sarcomas: An update of the indications of
    Rodríguez-Alfonso B; Simó-Perdigó M; Orcajo Rincón J
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):233-243. PubMed ID: 32616457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [18F-FDG-PET-CT in soft tissue sarcomas: when to image?].
    Rodríguez-Alfonso B; Mucientes Rasilla J; Mitjavila Casanovas M; Cardona Arboniés J; Cubedo R
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):43-9. PubMed ID: 24094372
    [No Abstract]   [Full Text] [Related]  

  • 18. Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis.
    Liu F; Zhang Q; Zhu D; Liu F; Li Z; Li J; Wang B; Zhou D; Dong J
    Medicine (Baltimore); 2015 Sep; 94(36):e1462. PubMed ID: 26356700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG PET/MR in initial staging of sarcoma: Initial experience and comparison with conventional imaging.
    Platzek I; Beuthien-Baumann B; Schramm G; Maus J; Laniado M; Kotzerke J; van den Hoff J; Schuler M
    Clin Imaging; 2017; 42():126-132. PubMed ID: 27951459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.